Multiple Myeloma
Multiple myeloma is a cancer of the plasma cells, a type of white blood cell that produces antibodies. It leads to the overproduction of abnormal plasma cells, which can cause bone damage and affect the immune system.
Self-Administration of Elranatamab for Multiple Myeloma
We are exploring whether patients with multiple myeloma can safely administer Elranatamab at home. The study will assess the feasibility, safety, and impact on quality of life for both patients and their caregivers.
What diseases are being studied?
Health conditions and diseases that the clinical trial is designed to study and treat.
Who can participate in the clinical trial?
These questions help us understand your situation so we can let the trial team know whether you might be a potential match. This is not a medical evaluation and is not part of the official screening, the study doctor will make the final decision..
- Are you at least 18 years old?
- Are you currently pregnant or breastfeeding?
- Do you have any significant medical conditions like HIV or active hepatitis?
- Have you had any prior treatment for multiple myeloma?
- Do you have a history of certain cancers other than multiple myeloma within the last 5 years?
Where is the clinical trial being conducted?
Locations and medical facilities where this clinical trial is currently recruiting or conducting research. Select the locations where you would like to participate.
Loading map...
Odense University Hospital
Department of Hematology
Odense, Denmark
Sponsor: Odense University Hospital
Last updated: Nov 27, 2025
Disclaimer: Parts of this content have been automatically extracted from the EU Clinical Trials registry. While we strive for accuracy, please always contact the trial site or sponsor directly for correct and official information before making any decisions about participation. View on EU Clinical Trials.